MedTrace Logo

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

NCT05429515 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-06-23

No results posted yet for this study

Summary

In patients with multiple myeloma-related acute kidney injury, compare the renal outcome of chemotherapy combined with HFR-SUPRA to chemotherapy combined with hemodialysis.

Conditions

Interventions

PROCEDURE

HFR-SUPRA

HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.

PROCEDURE

hemodialysis

hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.

DRUG

Chemotherapy

chemotherapy protocol will be made by hematologists.

Sponsors & Collaborators

  • Bellco Hoxen Medical (Shanghai) Co., Ltd

    collaborator UNKNOWN

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Yan Qin, MD · Peking Union Medical College Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2032-07-01
Completion
2032-12-01

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05429515 on ClinicalTrials.gov